Literature DB >> 33305893

Anti-tumour effects of a dual cancer-specific oncolytic adenovirus on Breast Cancer Stem cells.

Wenjie Li1,2,3, Yiquan Li2,3, Yingli Cui3,4, Shanzhi Li2,3, Yilong Zhu2,3, Chao Shang3, Gaojie Song3, Zirui Liu3, Zhiru Xiu2,3, Jianan Cong3, Tingyu Li3, Xiao Li1,2,3,5, Lili Sun3,6, Ningyi Jin1,2,3,5.   

Abstract

Apoptin can specifically kill cancer cells but has no toxicity to normal cells. Human telomerase reverse transcriptase (hTERT) can act as a tumour-specific promoter by triggering the expression of certain genes in tumour cells. This study aims to investigate the inhibitory effects and to explore the inhibitory pathway of a dual cancer-specific recombinant adenovirus (Ad-apoptin-hTERTp-E1a, Ad-VT) on breast cancer stem cells. Breast cancer cell spheres were obtained from MCF-7 cells through serum-free suspension culture. The cell spheres were detected by flow cytometry for CD44+ CD24- cell subsets. The stemness of MCF-7-CSC cells was confirmed by in vivo tumorigenesis experiments. The inhibitory effect of the recombinant adenoviruses on MCF-7-CSC cells was evaluated by CCK-8 assay. In addition, the stemness of adenovirus-infected MCF-7-CSC cells was analysed by testing the presence of CD44+ CD24- cell subsets. The ability of the recombinant adenovirus to induce MCF-7-CSC cell apoptosis was detected by staining JC-1, TMRM and Annexin V. Our results showed that a significantly higher proportion of the CD44+ CD24- cell subsets was present in MCF-7-CSC cells with a significantly increased expression of stem cell marker proteins. The MCF-7-CSC cells, whlist exhibited a strong tumorigenic ability with a certain degree of stemness in mice, were shown to be strongly inhibited by recombinant adenovirus Ad-VT through cell apoptosis. In addition, Ad-VT was shown to exert a killing effect on BCSCs. These results provide a new theoretical basis for the future treatment of breast cancer.
© 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.

Entities:  

Keywords:  apoptin; apoptosis; breast cancer stem cells; recombinant adenovirus

Mesh:

Substances:

Year:  2020        PMID: 33305893      PMCID: PMC7812255          DOI: 10.1111/jcmm.16113

Source DB:  PubMed          Journal:  J Cell Mol Med        ISSN: 1582-1838            Impact factor:   5.295


  39 in total

Review 1.  Evolution of the cancer stem cell model.

Authors:  Antonija Kreso; John E Dick
Journal:  Cell Stem Cell       Date:  2014-03-06       Impact factor: 24.633

2.  Prospective identification of tumorigenic breast cancer cells.

Authors:  Muhammad Al-Hajj; Max S Wicha; Adalberto Benito-Hernandez; Sean J Morrison; Michael F Clarke
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-10       Impact factor: 11.205

3.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell.

Authors:  D Bonnet; J E Dick
Journal:  Nat Med       Date:  1997-07       Impact factor: 53.440

Review 4.  Normal stem cells and cancer stem cells: the niche matters.

Authors:  Linheng Li; William B Neaves
Journal:  Cancer Res       Date:  2006-05-01       Impact factor: 12.701

5.  Cancer Stem Cells, Epithelial to Mesenchymal Markers, and Circulating Tumor Cells in Small Cell Lung Cancer.

Authors:  Milind Pore; Coby Meijer; Geertruida H de Bock; Wytske Boersma-van Ek; Leon W M M Terstappen; Harry J M Groen; Wim Timens; Frank A E Kruyt; T Jeroen N Hiltermann
Journal:  Clin Lung Cancer       Date:  2016-06-08       Impact factor: 4.785

Review 6.  Breast cancer stem cells: a novel therapeutic target.

Authors:  Sudeshna Gangopadhyay; Argha Nandy; Pooja Hor; Ashis Mukhopadhyay
Journal:  Clin Breast Cancer       Date:  2012-11-03       Impact factor: 3.225

Review 7.  Deadly crosstalk: Notch signaling at the intersection of EMT and cancer stem cells.

Authors:  Ingrid Espinoza; Lucio Miele
Journal:  Cancer Lett       Date:  2013-08-21       Impact factor: 8.679

8.  Sox2 promotes tamoxifen resistance in breast cancer cells.

Authors:  Marco Piva; Giacomo Domenici; Oihana Iriondo; Miriam Rábano; Bruno M Simões; Valentine Comaills; Inmaculada Barredo; Jose A López-Ruiz; Ignacio Zabalza; Robert Kypta; Maria d M Vivanco
Journal:  EMBO Mol Med       Date:  2014-01       Impact factor: 12.137

9.  Multiple drug resistance due to resistance to stem cells and stem cell treatment progress in cancer (Review).

Authors:  Chong DI; Yaodong Zhao
Journal:  Exp Ther Med       Date:  2014-12-16       Impact factor: 2.447

Review 10.  Embryonic stem cell markers.

Authors:  Wenxiu Zhao; Xiang Ji; Fangfang Zhang; Liang Li; Lan Ma
Journal:  Molecules       Date:  2012-05-25       Impact factor: 4.411

View more
  2 in total

Review 1.  Oncolytic Virotherapy Treatment of Breast Cancer: Barriers and Recent Advances.

Authors:  Amy Kwan; Natalie Winder; Munitta Muthana
Journal:  Viruses       Date:  2021-06-11       Impact factor: 5.048

2.  Anti-tumour effects of a dual cancer-specific oncolytic adenovirus on Breast Cancer Stem cells.

Authors:  Wenjie Li; Yiquan Li; Yingli Cui; Shanzhi Li; Yilong Zhu; Chao Shang; Gaojie Song; Zirui Liu; Zhiru Xiu; Jianan Cong; Tingyu Li; Xiao Li; Lili Sun; Ningyi Jin
Journal:  J Cell Mol Med       Date:  2020-12-11       Impact factor: 5.295

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.